Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric carboxymaltose versus usual care in iron-deficient chronic heart failure
NL-OMON41512Phase 3Active, not recruiting
- Sponsor
- CSL Vifor
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic heart failure (CHF) and iron deficiency anemia (IDA) comparing Ferric carboxymaltose with Standard of care (2 arms). Primary endpoint: Change in peak oxygen consumption from baseline to Week 24. Started Feb 2012; status: active, not recruiting.
02
Drugs
ferric carboxymaltose
03
Conditions
chronic heart failure (CHF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NL-OMON41512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41512.